Stockreport

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
PDF – Primary endpoint met in both trials –– Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate –– Chronic hepatitis B (CHB [Read more]